GlaxoSmithKline KK announced June 22 that it has introduced its anti-depressant Paxil CR Tablets in Japan after its National Health Insurance (NHI) price listing on the same day.
Paxil CR tablets contain a controlled-release formulation of anti-depressant Paxil tablets. It received regulatory approval in Japan on Jan. 18 to treat depression. The NHI price is 105.60 yen ($1.30) for a 12.5 mg tablet and 184.70 yen for a 25 mg tablet.
Overseas, the development of anti-depressants using new formulation technology is being conducted actively, and with the approval of Paxil CR Tablets, Japan has entered the era of controlled-release formulations.
Paxil CR Tablets were approved in the United States in 1999, and as of June 2011, have been approved and widely used in more than 40 countries.
- « Prev
- Next »